RASGRP1:APTX Gene Ratio Assay for AML Treatment Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for elderly acute myeloid leukemia (AML) patients are limited, with conventional induction therapy being toxic and often not offered due to poor outcomes. There is a need for rapid and accurate predictive assays to identify suitable treatment options for AML patients, particularly those with relapsed or refractory disease.
Innovation Solution
The use of a two-gene expression ratio assay, specifically RASGRP1:APTX, to predict response to farnesyl transferase inhibitor (FTI) combination treatments, such as tipifarnib with etoposide, allowing for personalized treatment decisions and switching to more effective therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional induction therapy is used to treat elderly AML patients, then remission rates improve (70% achieve remission), but toxicity and poor outcomes worsen the situation
Solution Approach 1:
The patent changes the treatment parameter from conventional induction therapy to farnesyl transferase inhibitors (FTIs), which have different mechanism of action and toxicity profiles. This parameter change allows treating elderly patients with less toxic therapy while maintaining reasonable response rates through biomarker-guided selection.
Solution Approach 2:
The patent replaces the conventional mechanical/chemical cytotoxic induction therapy with a different mechanism (FTI inhibition of farnesyl transferase), which selectively targets specific signaling pathways without the broad toxicity of conventional chemotherapy in elderly patients.
2Reliability
If cytogenetic evaluation is performed to identify favorable sub-groups, then treatment selection improves, but time delay worsens prognosis
Solution Approach 1:
The patent performs preliminary biomarker identification using rapid assays (RT-PCR, Flow Cytometry) that can be completed quickly to stratify patients before final treatment decision. This preliminary action enables faster treatment initiation while maintaining accurate patient selection through biomarker analysis.
Solution Approach 2:
The patent substitutes time-consuming cytogenetic evaluation with faster molecular and cellular assays (RT-PCR for mutations, Flow Cytometry for surface markers) that provide rapid biomarker data to guide treatment decisions without the lengthy waiting period of traditional cytogenetics.
3Object-affected harmful factors
If farnesyl transferase inhibitors are used to treat elderly AML patients, then toxicity is reduced, but response rate worsens (only 15-25% respond)
Solution Approach 1:
The patent applies local quality by identifying specific patient sub-groups with favorable biomarkers (RAS mutations, specific gene expressions) who are more likely to respond to FTIs. This allows concentrating the less toxic FTI therapy on the subset of patients most likely to benefit, rather than treating all elderly patients uniformly.
Solution Approach 2:
The patent changes the selection parameter from conventional therapy eligibility to biomarker-driven selection for FTI responsiveness. By using rapid biomarker assays to identify patients with specific molecular characteristics, the therapy can be directed at the optimal patient subset to improve response rates while maintaining the toxicity advantage.
4Loss of time
If rapid assays are implemented to speed up treatment decisions, then time loss is reduced, but measurement precision requirements increase
Solution Approach 1:
The patent substitutes complex, time-consuming cytogenetic analysis with faster molecular techniques (RT-PCR for point mutations, Flow Cytometry for surface markers) that provide rapid results. These alternative measurement systems maintain sufficient precision for clinical decision-making while dramatically reducing the time required for biomarker identification.
Data Source
AI summary
The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.